Alembic receives FDA OK for generic Depakote Sprinkle
Divalproex sodium is an anti-epileptic drug.
Alembic has received the Food and Drug Administration’s permission for divalproex sodium delayed-release capsules, 125 mg, which is the generic of AbbVie’s Depakote Sprinkle.
Divalproex sodium is an anti-epileptic drug indicated for monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures.
[Read more: Alembic intros generic Perforomist]
Divalproex sodium delayed-release capsules, 125 mg have a market value of roughly $61.1 million for the 12 months ending September 2024, per IQVIA.
[Read more: Alembic releases generic Pradaxa]